Navigation Links
NeuroPhage, Inc. Raises $6.4 Million In Additional Financing
Date:5/6/2013

CAMBRIDGE, Mass., May 6, 2013 /PRNewswire/ -- NeuroPhage Pharmaceuticals, Inc., a company developing breakthrough therapies for neurodegenerative diseases, today announced that it raised $6.4 million in a private equity financing round. Merieux Developpement led the financing with participation from all current Neurophage investors, including Shire LLC. The new funds will help support ongoing pre-IND studies for lead compound NPT002 and will advance the development of second-generation fusion proteins with the potential for treating several neurodegenerative conditions including Alzheimer's, Parkinson's and Huntington's diseases. Separately, NeuroPhage announced that current Director John F. Dee has been named Chairman of the Board and Kenneth A. Buckfire has joined as a Director.

"We are encouraged by NeuroPhage's progress in further elucidating the mechanism of action of NPT002 and advancing the program toward clinical trials, as well as its discovery of new antibody-like fusion proteins with the potential to broadly address neurodegenerative disease markets with enormous unmet need," said Dr. Valerie Calenda , Partner at Merieux Developpement. "We believe the company's transformative approach to addressing protein misfolding could make a major contribution to achieving greatly improved treatments for these disabling conditions that affect millions of people worldwide."

Deposits of misfolded proteins in the brain are associated with many neurodegenerative diseases.  NPT002 has demonstrated the ability to safely and effectively mediate clearance of misfolded protein deposits (including amyloid-beta, tau and alpha-synuclein) in multiple animal models of neurodegenerative disease, resulting in cognitive and behavioral improvements. Following a successful pre-IND meeting with the FDA, NeuroPhage
'/>"/>

SOURCE NeuroPhage Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Minimally Invasive Devices Raises $9 Million in Series B Financing to Commercialize Laparoscopic Visualization Product
2. PCMA: New Report Shows Drugstore Lobby Agenda Raises Rx Costs for Small Businesses, Government Programs
3. Promotion Raises Awareness of Scar Treatment
4. MacuLogix Raises $3.6 Million in Series A Round
5. Leader In At-Home Laboratory Testing Praises Federal Panels Recommendations For Widespread HIV Testing
6. Cardioxyl Pharmaceuticals Raises $28 Million In Series B Financing Led By OrbiMed Advisors
7. Bayers Second Annual Virtual Walk for Hemophilia Raises Funds, Generates Excitement in the Hemophilia Community
8. Perrigo Reports Record First Quarter Revenue And Adjusted Earnings And Raises Full Year Adjusted EPS Guidance
9. Elekta Raises $52,200 to Support Individuals with Cancer
10. Cardinal Health Board Of Directors Raises Quarterly Dividend
11. BiO2 Medical Raises $12M in Series C Funding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO ... therapies for operable and inoperable solid tumor cancers, announced today ... 7 th Annual Phacilitate Immunotherapy Forum in ... Phacilitate will take place on January 26 at 10:30 a.m. ...
(Date:1/23/2015)... 2015 More than a third of reproductive-aged women enrolled ... private insurance, filled a prescription for an opioid pain medication ... week,s Morbidity and Mortality Weekly Report (MMWR). ... moderate to severe pain.  They are also found in some ...
(Date:1/23/2015)... , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ... directors of Advaxis, Inc. ("Advaxis" or the "Company") (NASDAQ: ... breached its fiduciary duties to shareholders. On ... investing website reporting that Advaxis had misrepresented the clinical ...
Breaking Medicine Technology:NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2
... 29, 2011 The Female Health Company (Nasdaq: ... conference call to discuss its operating results for the third ... 5, 2011 at 11:00 a.m. Eastern Time (EDT).  The Company ... Shareholders and other interested parties may participate ...
... AMGN ) reported total revenue increased 4 percent ... $3,804 million in the second quarter of 2010.  Total product ... to $3,893 million versus $3,613 million in the second quarter ... quarter of 2011 included a decline in other revenue due ...
Cached Medicine Technology:The Female Health Company to Host Third Quarter Conference Call on Friday, August 5, 2011 2Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion 2Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion 3Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion 4Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion 5Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion 6Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion 7Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion 8Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion 9Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion 10Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion 11Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion 12Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion 13Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion 14Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion 15Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion 16Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion 17Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion 18Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion 19
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of ... area has treated just about every type of injury that can ... for those same twenty-plus years, the team at Doctors on ... the best possible doctor. With the combined breadth of ...
(Date:1/22/2015)... 2015 Joan Lunden, award-winning American journalist, ... the upcoming 32nd Annual Miami Breast Cancer Conference ... Resource®, LLC (PER®) , shares that “a fast-growing, virulent” ... if she had not followed up her clean mammogram ...
(Date:1/22/2015)... 22, 2015 Yesterday, Senator Holly ... and Kristin Olsen (R-Modesto) were honored by the ... advancing biotechnology, biomedical science, medical device and pharmaceutical ... received the “2014 Life Sciences Champion” award from ...
(Date:1/22/2015)... Florida (PRWEB) January 22, 2015 IsoComforter, Inc. ... therapy machine with patented IsoTube design to treat specific body ... introduced the most progressive and easy to use patented cold ... post-operative and sports related orthopedic and muscle injuries. IsoComforter ...
(Date:1/22/2015)... January 22, 2015 Payday lending practices ... communities and cause financial distress to the states that ... at Howard University’s Center on Race and Wealth. , ... economic activity, payday loans at the same time substantially ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2
... doctors say sunitinib,s benefits outweigh its risks , , WEDNESDAY, ... sunitinib (Sutent) can cause high blood pressure in patients ... echoes the results of a study published last month ... risk of heart failure among patients with stomach cancer. ...
... Mich. One in four Americans in the hospital right ... get a urinary tract infection from that catheter. All of ... , And with every new case, UTIs will retain ... percent of infections related to hospitalization. , But despite ...
... University of California, San Francisco are reporting significant results ... the safe removal of tumors near language pathways in ... reduces the amount of time a patient must be ... study provides new data that refines scientists understanding of ...
... a non-invasive way to determine the existence and extent ... of pharmacologic strategies to combat the condition. These findings ... published by John Wiley & Sons on behalf of ... (AASLD). The article is also available online at Wiley ...
... most common cause of disability in the United States. ... continues to age, the toll of this disease will escalate. ... burden and its impact on our nations health care and ... by any form of arthritisis critical. , The National Arthritis ...
... of chemicals in red wine grapes may significantly reduce ... a study published recently in the Journal of Agricultural ... present in large amounts in fermented seeds and skins ... ability of bacteria to contribute to tooth decay. Beyond ...
Cached Medicine News:Health News:New Cancer Drug Boosts Blood Pressure 2Health News:New Cancer Drug Boosts Blood Pressure 3Health News:Catheter chaos: Hospitals lag in preventing common infection 2Health News:Catheter chaos: Hospitals lag in preventing common infection 3Health News:Catheter chaos: Hospitals lag in preventing common infection 4Health News:Language centers revealed, brain surgery refined with new mapping 2Health News:Language centers revealed, brain surgery refined with new mapping 3Health News:MRI techniques evolving towards better assessment of liver fibrosis 2Health News:The prevalence and impact of arthritis and other rheumatic conditions in the United States 2Health News:The prevalence and impact of arthritis and other rheumatic conditions in the United States 3Health News:Winemaking waste proves effective against disease-causing bacteria in early studies 2Health News:Winemaking waste proves effective against disease-causing bacteria in early studies 3Health News:Winemaking waste proves effective against disease-causing bacteria in early studies 4
The D.O.R.C. Silicone Oil is an ultra purified silicone oil which leads a maximum interfacial tension and minimizes interactions between tissues, cells and endo-tamponades media. (Sterile, 10 ml.)...
Eftiar® offers the vitreoretinal surgeon a temporary tamponade for efficient re-attachment of the retina, release of subretinal fluid, dissection of fibro-vascular proliferation and controlling r...
ROB-NEL Catheters (100% Latex-Free)...
Silver Foley Catheter 2-way...
Medicine Products: